Pulmatrix News

LEXINGTON, Mass.-- --May 21, 2012 - Pulmatrix , a biotechnology company developing breakthrough therapies for respiratory diseases, today announced the results of a clinical study showing that an iCALM attenuated allergen-induced bronchitis in susceptible asthmatic patients.

LEXINGTON, Mass. -- -- Pulmatrix , a biotechnology company developing breakthrough therapies for respiratory diseases, today announced that six posters on its iCALM and iSPERSE inhaled drug platforms have been selected for presentation at the American Thoracic Society 2012 International Conference taking place May 18-23, 2012, in San Francisco, CA.

LEXINGTON, Mass.-- --May 15, 2012 - Pulmatrix , a biotechnology company developing breakthrough therapies for respiratory diseases, today announced that its iSPERSE inhaled drug delivery platform demonstrated the capability to formulate a wide range of drugs for inhaled administration, including antibiotics, antibodies and other macromolecules.

LEXINGTON, Mass.-- --Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced that the European Patent Office has granted Pulmatrix's patent number EP 2315580 B1 entitled "Pharmaceutical formulations and methods for treating ... (more)

LEXINGTON, Mass.-- --Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that its iSPERSEa inhaled drug platform demonstrated multi-drug delivery capability and superiority over conventional lactose blending for an ... (more)